Here, combining either K-975 (or an alternate TEAD inhibitor, MYF-01-037) with osimertinib resulted in either complete or a significant reversal of osimertinib resistance in NF2 deleted PC-9, HCC827 or HCC4006 cancer cells (Supplementary Figs. 9a–g)5. This evidence concerns the gene NF2 and cancer.